The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients
- PMID: 22639291
- DOI: 10.1210/jc.2012-1533
The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients
Abstract
Context: Decisions regarding initial therapy and subsequent surveillance in patients with differentiated thyroid cancer (DTC) depend upon an accurate assessment of the risk of persistent or recurrent disease.
Objective: The objective of this study was to examine the predictive value of a single measurement of serum thyroglobulin (Tg) just before radioiodine remnant ablation (preablation Tg) on subsequent disease-free status.
Data sources: Sources included MEDLINE and BIOSYS databases between January 1996 and June 2011 as well as data from the author's tertiary-care medical center.
Study selection: Included studies reported preablation Tg values and the outcome of initial therapy at surveillance testing or during the course of long-term follow-up.
Data extraction: Two investigators independently extracted data and rated study quality using the Quality Assessment of Studies of Diagnostic Accuracy included in Systematic Reviews-2 (QUADAS-2) tool.
Data synthesis: Fifteen studies involving 3947 patients with DTC were included. Seventy percent of patients had preablation Tg values lower than the threshold value being examined. The negative predictive value (NPV) of a preablation Tg below threshold was 94.2 (95% confidence interval = 92.8-95.3) for an absence of biochemical or structural evidence of disease at initial surveillance or subsequent follow-up. The summary receiver operator characteristic curve based on a bivariate mixed-effects binomial regression model showed a clustering of studies using a preablation Tg below 10 ng/ml near the summary point of optimal test sensitivity and specificity.
Conclusion: Preablation Tg testing is a readily available and inexpensive tool with a high NPV for future disease-free status. A low preablation Tg should be considered a favorable risk factor in patients with DTC. Further study is required to determine whether a low preablation Tg may be used to select patients for whom radioiodine remnant ablation can be avoided.
Similar articles
-
THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER - CLINICAL CONSIDERATIONS.Acta Clin Croat. 2018 Sep;57(3):518-527. doi: 10.20471/acc.2018.57.03.16. Acta Clin Croat. 2018. PMID: 31168186 Free PMC article. Review.
-
Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.Surgery. 2013 Jun;153(6):828-35. doi: 10.1016/j.surg.2012.12.008. Epub 2013 Mar 13. Surgery. 2013. PMID: 23489940
-
Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.Clin Nucl Med. 2011 Dec;36(12):1102-5. doi: 10.1097/RLU.0b013e3182291c65. Clin Nucl Med. 2011. PMID: 22064080
-
Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma.Clin Endocrinol (Oxf). 2007 Jan;66(1):58-64. doi: 10.1111/j.1365-2265.2006.02685.x. Clin Endocrinol (Oxf). 2007. PMID: 17201802
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
Cited by
-
Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer.J Clin Med. 2024 Apr 23;13(9):2463. doi: 10.3390/jcm13092463. J Clin Med. 2024. PMID: 38730992 Free PMC article. Review.
-
Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.Endocrine. 2024 May 2. doi: 10.1007/s12020-024-03844-x. Online ahead of print. Endocrine. 2024. PMID: 38696058
-
Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.Arch Endocrinol Metab. 2024 Apr 4;68:e220506. doi: 10.20945/2359-4292-2022-0506. Arch Endocrinol Metab. 2024. PMID: 38578436 Free PMC article.
-
Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.Front Endocrinol (Lausanne). 2024 Jan 17;14:1307325. doi: 10.3389/fendo.2023.1307325. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38298190 Free PMC article.
-
Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.Endocrine. 2024 Jun;84(3):1081-1087. doi: 10.1007/s12020-024-03691-w. Epub 2024 Feb 1. Endocrine. 2024. PMID: 38296913
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous